Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Autor: Goette, A, Merino, JL, Ezekowitz, MD, Zamoryakhin, D, Melino, M, Jin, J, Mercuri, MF, Grosso, MA, Fernandez, V, Al-Saady, N, Pelekh, N, Zenin, S, Batushkin, V, Lip, GYH, Weitz, J, Freemantle, N, Klein, H, Buller, H, Segers, A, Roos, Y, Slagboom, T, Thijs, V, van Mechelen, R, Larrey, D, Laleman, W, Heidbuchel, H, Goudev, A, Rasmussen, L, Le Heuzey, JY, Glikson, M, Banach, M, Ruda, M, Lundqvist, CB, Ezekowitz, M, Gwechenberger, M, Huber, K, Purerfellner, H, Roithinger, F, Scherr, D, Stuhlinger, M, Delforge, M, Rivero-Ayerza, M, Thoeng, J, Vervoort, G, Vijgen, J, Willems, R, Benov, H, Dimov, B, Nikolov, F, Godev, A, Jorgova-Makedonska, J, Lazov, P, Marchev, S, Mihov, L, Petranov, S, Raev, D, Stoyanov, M, Tarnovska-Kadreva, R, Todorov, G, Tumbev, H, Cermak, O, Slany, N, Jarkovsky, P, Kautzner, J, Lukac, B, Nadenickova, P, Peterka, K, Slaby, J, Spinar, J, Vesely, J, Vitovec, M, Zavada, F, Al-Hashimi, S, Bronnum-Schou, J, Egstrup, K, Frost, L, Gislason, G, Lomholdt, J, Malczynski, J, Moller, DS, Nielsen, T, Raymond, I, Riahi, S, Tuxen, C, Cohen, A, Cottin, Y, Defaye, P, Deharo, JC, Depuis, JM, Elbaz, M, Ferrari, E, Gosse, P, Goube, P, Paganelli, F, Pineau, J, Piot, O, Biermann, J, Bosch, R, Brachmann, J, Darius, H, Dengler, T, Hartmann, A, Kreis, I, Lamparter, S, Licka, M, Maier, L, Schellong, S, Schmitt, J, Stellbrink, C, Walkili, R, Willems, S, vom Dahl, J, Dezsi, A, Edes, I, Laszlo, S, Lupkovics, G, Matoltsy, A, Merkely, B, Nagy, A, Nagy, L, Palinkas, A, Simor, T, Tomcsanyi, J, Toth, L, Alcalai, R, Hayek, T, Katz, A, Mazen, E, Shechter, M, Shochat, M, Zeltser, D, Zimlichman, R, Boriani, G, De Caterina, R, Di Pasquale, G, Fattore, L, Grimaldi, M, Gulizia, M, Mazzone, C, Themistoclakis, S, Volpe, M, Allaart, C, de Groot, J, Elvan, A, Folkeringa, R, Hazeleger, R, Jansen, W, Nierop, P, Willems, A, de Ruiter, G, Czarnecka, D, Gniot, J, Januszewicz, A, Jaworska, K, Loboz-Grudzien, K, Niezgoda, K, Ptaszynski, P, Wysokinski, A, Bartos, D, Bengus, C, Bolohan, R, Chioncel, O, Coman, IM, Crisu, D, Dan, GA, Dobreanu, D, Dumitrescu, S, Gurghean, A, Lighezan, D, Militaru, C, Minescu, B, Podoleanu, CCG, Pop, C, Popescu, MI, Rosu, RO, Tase, A, Voicu, OC, Belenky, D, Bolshakova, O, Chumakova, G, Demko, A, Goloshchekin, B, Kostenko, V, Kuznetsov, V, Libov, I, Nevzorova, V, Nikolaev, K, Popov, S, Shubik, Y, Staroverov, I, Timofeev, A, Zrazhevskiy, K, Valladares, FA, Lopez, MA, Arenal, A, Gonzalez, VB, Cosin-Sales, J, Gonzalez-Juanatey, JR, Rubio, AM, Martinez, JG, Falconi, E, Mont, L, Bermejo, MAP, Sabate, X, Camano, MV, Vida, M, Vinolas, X, Gomez, JLZ, Lindquist, CB, Fredholm, O, Savelieva, I, Haywood, G, Aggarwal, R, Bakhai, A, Balasubramaniam, R, Betts, T, Campbell, P, Choy, AM, Davis, G, Izzat, L, Kadr, H, Lindsay, S, Lip, G, More, R, Ng, GA, Payne, G, Schilling, R, Senior, R, Tayebjee, M, Travill, C, Rishko, M, Fushtey, I, Karpenko, O, Karpenko, Y, Klantsa, A, Kraiz, I, Kushnir, M, Kutniy, O, Parkhomenko, A, Petrovskyy, R, Reshotko, D, Stanislavchuk, M, Sychov, O, Tseluyko, V, Vasylets, V, Minakova, PO, Volkov, D, Zharinov, O, Zhurba, S, Bahu, M, Bashir, F, Berk, M, Cheirif, J, Clay, A, Crenshaw, J, Ellenbogen, K, Ganeshram, V, Halpern, S, Heiman, M, Henderson, D, Ho, A, Kovach, T, Mckenzie, M, Nadar, V, Penny-Peterson, E, Rao, S, Sawhney, N, Shaoulian, E, Sheikh, K, Torres-Heisecke, R, Weiss, R

Publikováno v: LANCET
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy. Few safety data about ed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::b7a4a252c8115523ed157c180c6503f7
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14350

Long Term Prognosis in Very Young Patient with Acute Coronary Syndrome

Autor: Yagel, O., Shadafny, N., Hamerman-Rossenberg, A., Alcalai, R.

Publikováno v: In Indian Heart Journal November 2019 71 Supplement 1:S52-S52